vs
Side-by-side financial comparison of Doximity, Inc. (DOCS) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Doximity, Inc. is the larger business by last-quarter revenue ($185.1M vs $103.7M, roughly 1.8× Twist Bioscience Corp). Doximity, Inc. runs the higher net margin — 33.3% vs -29.4%, a 62.7% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs 9.8%).
Doximity is an online networking service for medical professionals. Launched in 2010, the platform offers its members curated medical news, telehealth tools, and case collaboration.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
DOCS vs TWST — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $185.1M | $103.7M |
| Net Profit | $61.6M | $-30.5M |
| Gross Margin | 89.9% | 52.0% |
| Operating Margin | 38.9% | -31.7% |
| Net Margin | 33.3% | -29.4% |
| Revenue YoY | 9.8% | 16.9% |
| Net Profit YoY | -18.1% | 3.4% |
| EPS (diluted) | $0.31 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $185.1M | $103.7M | ||
| Q3 25 | $168.5M | — | ||
| Q2 25 | $145.9M | — | ||
| Q1 25 | $138.3M | — | ||
| Q4 24 | $168.6M | — | ||
| Q3 24 | $136.8M | — | ||
| Q2 24 | $126.7M | — | ||
| Q1 24 | $118.1M | — |
| Q4 25 | $61.6M | $-30.5M | ||
| Q3 25 | $62.1M | — | ||
| Q2 25 | $53.3M | — | ||
| Q1 25 | $62.5M | — | ||
| Q4 24 | $75.2M | — | ||
| Q3 24 | $44.2M | — | ||
| Q2 24 | $41.4M | — | ||
| Q1 24 | $40.6M | — |
| Q4 25 | 89.9% | 52.0% | ||
| Q3 25 | 90.3% | — | ||
| Q2 25 | 89.2% | — | ||
| Q1 25 | 89.5% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 90.0% | — | ||
| Q2 24 | 89.3% | — | ||
| Q1 24 | 89.4% | — |
| Q4 25 | 38.9% | -31.7% | ||
| Q3 25 | 37.8% | — | ||
| Q2 25 | 37.4% | — | ||
| Q1 25 | 35.2% | — | ||
| Q4 24 | 47.4% | — | ||
| Q3 24 | 38.8% | — | ||
| Q2 24 | 36.4% | — | ||
| Q1 24 | 35.5% | — |
| Q4 25 | 33.3% | -29.4% | ||
| Q3 25 | 36.8% | — | ||
| Q2 25 | 36.5% | — | ||
| Q1 25 | 45.2% | — | ||
| Q4 24 | 44.6% | — | ||
| Q3 24 | 32.3% | — | ||
| Q2 24 | 32.7% | — | ||
| Q1 24 | 34.4% | — |
| Q4 25 | $0.31 | $-0.50 | ||
| Q3 25 | $0.31 | — | ||
| Q2 25 | $0.27 | — | ||
| Q1 25 | $0.31 | — | ||
| Q4 24 | $0.37 | — | ||
| Q3 24 | $0.22 | — | ||
| Q2 24 | $0.21 | — | ||
| Q1 24 | $0.20 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $64.8M | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $979.3M | $456.1M |
| Total Assets | $1.2B | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $64.8M | $197.9M | ||
| Q3 25 | $169.2M | — | ||
| Q2 25 | $137.3M | — | ||
| Q1 25 | $209.6M | — | ||
| Q4 24 | $165.3M | — | ||
| Q3 24 | $184.2M | — | ||
| Q2 24 | $111.4M | — | ||
| Q1 24 | $96.8M | — |
| Q4 25 | $979.3M | $456.1M | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $961.2M | — | ||
| Q2 24 | $913.6M | — | ||
| Q1 24 | $901.4M | — |
| Q4 25 | $1.2B | $638.1M | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $60.9M | $-24.8M |
| Free Cash FlowOCF − Capex | — | $-34.8M |
| FCF MarginFCF / Revenue | — | -33.5% |
| Capex IntensityCapex / Revenue | — | 9.6% |
| Cash ConversionOCF / Net Profit | 0.99× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.9M | $-24.8M | ||
| Q3 25 | $93.9M | — | ||
| Q2 25 | $62.1M | — | ||
| Q1 25 | $98.5M | — | ||
| Q4 24 | $65.2M | — | ||
| Q3 24 | $68.3M | — | ||
| Q2 24 | $41.2M | — | ||
| Q1 24 | $63.9M | — |
| Q4 25 | — | $-34.8M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -33.5% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 9.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | 0.99× | — | ||
| Q3 25 | 1.51× | — | ||
| Q2 25 | 1.16× | — | ||
| Q1 25 | 1.58× | — | ||
| Q4 24 | 0.87× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.00× | — | ||
| Q1 24 | 1.57× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
